Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress

SIMPLE SUMMARY: The prognosis for patients with locoregionally advanced and metastatic melanoma remains poor despite advances in systemic therapy. By delivering therapeutics directly to the site(s) of disease, intralesional therapies have the advantage of delivering the oncolytic agent directly into...

Descripción completa

Detalles Bibliográficos
Autores principales: DePalo, Danielle K., Zager, Jonathan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000422/
https://www.ncbi.nlm.nih.gov/pubmed/36900196
http://dx.doi.org/10.3390/cancers15051404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000422/
https://www.ncbi.nlm.nih.gov/pubmed/36900196
http://dx.doi.org/10.3390/cancers15051404

Ejemplares similares